Commercial strategy for orthopedic, spine and biologics companies, from former device executives.
We work beside your leadership team to sharpen the pitch, open doors with hospitals, surgeons and distributors, and prepare the company for financing and exit.
Beyond the superb industry relationships the team had established, it was obvious to the surgeons we approached that this was an atypical sales model.
100+ yearscombined in musculoskeletal commercialization
12–18 motypical engagement, on a shared-risk model
- OrthopedicsImplants, instrumentation, ASC strategy
- SpinePorous titanium, additive manufacturing
- BiologicsRegenerative and anti-inflammatory
- Wound careHuman tissue and biologic products
We have taken companies through every phase of the corporate timeline.
Most organizations stumble in the same three places. Our partners have the knowledge and relationships to carry you through them.
Where most companies stumbleWhere we accelerate
- 01
Messaging and launch
Define the pitch and test it against the rep, the surgeon and the hospital.
- 02
Market access
Hospital, IDN and ASC access through supply-chain relationships.
- 03
Commercial scale
Distributor networks, sales infrastructure and inventory at scale.
- 04
Financing
The story, governance and diligence readiness to raise capital.
- 05
Exit
M&A preparation, valuation narrative and exit strategy.
Taking the product to market
- Product messagingSales are won in the first minutes. We refine the pitch for every audience.
- Market accessHospital and ASC access built on existing relationships.
- Sales optimizationA strategic sales plan, with hands-on support through implementation.
- MarketingContent calendar, design and collateral in front of the right audiences.
Building the company behind it
- OperationsReliable inventory management that uses economies of scale.
- Data and financeDashboards, budgets and pro-formas your board can act on.
- GovernanceCorporate infrastructure, key advisor appointments, long-term planning.
- Capital and exitFundraising preparation, M&A and exit strategy.
A strategy has to hold up with three people.
Every plan we build is pressure-tested against the rep who carries it, the surgeon who uses it, and the hospital that buys it.
We get in, deliver, and get out.
Optimize
Align with leadership on the organization’s needs, then set up a shared-risk program.
Market access · Corporate governance · Business development · M&A
Strategize
Find the synergies that turn an innovation into adoption, with patient care as the measure.
Service models · Portfolio enhancement · Competitive positioning · Sales strategy
Prioritize
Put resources behind the moves that matter and track each against the plan.
Implementation · Finance and budgeting · Pro-formas · Exit strategy
Case studies
All case studiesEmerging Implant Technologies
The first manufacturer to focus only on additively manufactured porous-titanium spinal implants, designed around the latest science on bone ingrowth.
Read the case study →Axolotl Biologix
Human biologics that reduce inflammation and foster regeneration across orthopedic, wound care and aesthetic indications.
Read the case study →By every metric, we’re head and shoulders ahead of where we were a year ago. New processes are in place, inventory costs are down and supplier performance is greatly improved.
The partners
Meet the full teamJosh Sandberg
Founding PartnerMedtech executive who has incubated multiple companies, with two successful exits.John Limpic
Managing DirectorSales leader who has scaled high-growth companies from $0 to more than $100M.Tony Passalacqua
PartnerSupply chain, logistics and back-office operations in musculoskeletal.Aaron Tabor, PhD
Chief Science OfficerMusculoskeletal pathology specialist and author of clinical documentation.